Senior Transaction Advisor, California
Sandi joined FPG in 2019 to bring deep industry expertise not only to the evaluative phase of Ferghana’s workflow, but also to execution of transactions in the biopharma and diagnostic sectors.
Sandi has more than 20 years of executive and entrepreneurial experience in the pharmaceutical and biotechnology industry, with specialization in oncology, hematology and infectious diseases. Her global business experience encompasses executive management, commercial operations, strategic business development, licensing, M&A, franchise development, market access and health policy influence.
In her role of consultant to corporates, Sandi has championed the successful development of strategic clinical and commercialization plans that led to successful product regulatory approvals (FDA, EMA, and international markets), label expansions, life cycle management, licensing deals and corporate M&A transactions.
Sandi began her pharmaceutical career with Eli Lilly’s Hospital Division and later on, was one of the first hires for the Bristol Myers Oncology Franchise. Sandi spent 16 years with BMS in varying positions of increasing global responsibility with P&L responsibilities exceeding $2B. Following her years at BMS, Sandi spent two years at Amgen focusing on market expansion of the Neupogen Franchise.
Most recently, Sandi acted as advisor to a private Investment firm , reviewing investment opportunities.
Sandi earned her Bachelor of Science degree from the University of Manitoba with Honors and her Masters of Business Administration from the Canadian Institute of Management. She is the recipient of several outstanding service awards, honors and distinctions including Guest Lecturer at Wharton School of Business.